Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.79 million versus the consensus estimate of $1.74 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.